ALS pill trial halted: what we know about SPG302's Long-Term safety

NCT ID NCT06903286

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study looked at the long-term safety and effectiveness of a daily oral medication called SPG302 in people with ALS who had already taken part in an earlier study. The trial was stopped early, and only 16 people were enrolled. Researchers tracked side effects, suicidal thoughts, and changes in daily function. Because ALS requires ongoing management and there is no cure, this trial aimed to control the disease rather than eliminate it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Flinders Medical Center

    Adelaide, South Australia, 5042, Australia

  • Macquarie University

    North Ryde, New South Wales, 2109, Australia

  • Royal Brisbane and Women's Hospital

    Herston, Queensland, 4029, Australia